EZH2 and non-small cell lung carcinoma: Among the NSCLC medical records included in the study, EZH2 mRNA had a high expression in 962 cases with a median survival time of 54.17 months and a low expression in 964 cases with a median survival time of 79.50 months (HR = 1.31and 95% CI 1.15~1.48; p < 0.05) (Figure 3(a)).